This is a hedged equity strategy. Our equity portfolio is an all cap diversified portfolio invested in large, mid and small cap US equities that Alpha DNA believes will out-perform Wall Street's expectations for growth in EPS and Revenue. Alpha DNA uses machine learning and alternative data sources to optimize its stock selection. The portfolio is actively managed and rebalanced regularly. The equity portfolio is biased towards mid and small cap positions. The portfolio also includes a hedge using put options on an ETF that tracks the Russell 2000. The hedge is intended to provide downside protection in the event of a material market decline. This strategy is formerly known as the IAS Equity Long Short strategy.

All Returns below are reported Net of Fees. You can adjust the time period for the returns but the default time period is since inception.

Historic Returns
Return Statistics
Quantitative Statistics
Year Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec YTD
2024 -1.01% 6.50% 2.37% - - - - - - - - - 7.92%
2023 3.47% 1.64% -1.75% -4.15% 1.46% 6.77% 3.12% -5.33% -5.18% -5.71% 8.34% 7.61% 9.17%
2022 -8.54% -1.60% -2.30% -6.25% 2.50% -9.27% 8.47% -1.71% -2.46% 8.52% 1.38% -5.02% -16.70%
2021 5.00% 3.35% 1.12% 4.67% -1.16% 2.15% -0.83% 2.17% -4.28% 2.12% 2.59% -0.41% 17.35%
2020 2.72% -3.35% -4.57% 11.11% 6.47% 2.45% 4.08% 3.24% -3.40% -1.08% 8.34% 4.33% 33.26%
2019 2.60% 1.53% -2.17% 0.74% -5.54% 6.06% 1.49% -2.59% -2.81% 0.77% 6.57% 1.63% 7.86%
2018 1.60% -3.22% 1.06% -2.22% 6.82% 0.75% -1.09% 6.50% -2.52% -7.17% -1.09% -5.62% -6.95%
2017 0.79% 0.59% 1.98% 1.52% -1.80% 2.77% 3.36% -1.73% 4.86% 0.94% 2.47% -1.56% 14.88%
2016 0.45% -2.27% -0.91% 0.13% 1.58% 0.44% -0.41% -1.29% 4.64% -3.79% 2.21% 1.81% 2.34%
2015 1.01% -0.99% -0.77% -0.77% -0.95% 1.06% 2.73% -1.99% 1.26% -2.20% 0.93% 2.50% 1.68%
2014 - - - - - - - - - - 1.02% 0.18% 1.20%
  Alpha DNA All Cap Hedged Equity HFRI Quantitative Directional Index
Cumulative Return: 86.37% 90.09%
1 Year Return: 14.03% 20.40%
3 Year Return (Annual): 1.63% 9.34%
5 Year Return (Annual): 10.19% 9.91%
Standard Deviation (Annual): 13.26% 7.73%
Downside Deviation (Annual): 8.08% 4.61%
  Alpha DNA All Cap Hedged Equity HFRI Quantitative Directional Index
Sharpe Ratio (Annualized): 0.20 0.29 %
Sortino (Annualized): 0.20 0.37

 

Alpha DNA All Cap Hedged Equity vs. HFRI Quantitative Directional Index
Beta: 1.18
Alpha: -0.08
R Squared: 0.48

Note: Alpha DNA Investment Management is a registered investment adviser and investment manager that specializes in quant equity strategies. Alpha DNA is a separate accounts manager and all returns expressed herein are solely from the separate accounts business within Alpha DNA. 

Alpha DNA All Cap Hedged Equity Composite includes all institutional and retail portfolios that invest in a diversified portfolio of over 50 total U.S. equity positions – either long and/ or short. The strategy aims to reduce systematic market risk by identifying the stocks most likely to out- perform other stocks based on changing demand. Risk is further mitigated by implementation in market neutral posture when the research indicates potential for a downward market. The portfolio is designed to find picks that will out- perform the counter- parts. The Internet Advantage Strategies is a series of strategies based on an innovative new research approach; ALPHA tracks the digital Internet footprint of publicly traded companies to find hidden demand trends in the market place. This composite includes all portfolios that were at least 70% dedicated to this strategy. The benchmark is the HFRI Quantitative Directional Equity Hedge Fund Index. 

The HFRI Quantitative Directional Equity Hedge Fund Index is a subset of the HFRI Equity Hedge Fund Index that measures the aggregate performance of equity hedge funds that employ quantitative strategies that can use long and short equity positions and the portfolio can be positioned net long or net short. There is no minimum account size for this composite. The Alpha DNA All Cap Hedged Equity Composite was created AUGUST 1, 2017. The inception date of the strategy is November 1, 2014. 

Alpha DNA claims compliance with the Global Investment Performance Standards (GIPS*). To receive a full list of composite descriptions of Alpha DNA and/ or a presentation that complies with the GIPS* standards, contact Wayne Ferbert at (443)-288-6444 or wayne.ferbert@alphadnaim.com. Returns are presented net of fees and include the reinvestment of all income. Performance presented prior to August 2017 occurred while the Portfolio Manager was affiliated with a prior firm and the Portfolio Manager was the only individual responsible for selecting the securities to buy and sell. The prior firm track record conforms to the portability requirements of the GIPS standards. GIPS® is a registered trademark of CFA Institute. CFA Institute does not endorse or promote this organization, nor does it warrant the accuracy or quality of the content contained herein. 

These results should not be viewed as indicative of the advisor’s skill.  The prior performance figures indicated herein represent portfolio performance for only a short time period, and may not be indicative of the returns or volatility each portfolio will generate over a long time period. The performance presented should also be viewed in the context of the broad market and general economic conditions prevailing during the periods covered by the performance information. The actual results for the comparable periods would also have varied from the presented results based upon the timing of contributions and withdrawals from individual client accounts. The performance figures contained herein should be viewed in the context of the various risk/ return profiles and asset allocation methodologies utilized by the asset allocation strategists in developing their model portfolios, and should be accompanied or preceded by the model.